Most gut-treatment writing online sits at one of two extremes: clinical caution that says nothing actionable, or confident protocols with no evidence behind them. These guides aim for the middle - specific and practical where the evidence allows, explicit about what is licensed, what is off-label, and what is still only a laboratory finding.
Before you read on: several treatments below are used off-label in the UK - meaning they are not licensed for that purpose. Off-label prescribing is legal and sometimes appropriate, but it shifts responsibility onto the prescriber and should always be supervised. Nothing here is a recommendation to self-treat.
The gut-selective antibiotic most associated with SIBO and IBS-D. Licensing, off-label use, NHS vs private access, realistic costs and safety.
Read the guide Treatment guideA non-absorbed antifungal that acts only in the gut lumen. UK dosing, off-label SIFO protocols, die-off vs allergy, and interactions.
Read the guide Research noteA 2023 lab study on potentiating nystatin against candida biofilms - what the “32-fold” headline really means, and why it is not yet a treatment.
Read the noteSome treatments are best understood in the context of the condition they target, so they live inside the pillar guides rather than as standalone pages:
How to read the evidence tags: across these guides, claims are graded - strong (regulatory sources or randomised trials), moderate (smaller or observational studies), weak (single small studies or expert opinion) and mechanistic / in-vitro (laboratory plausibility only). The grade matters as much as the claim.
Considering an off-label treatment and want it done properly?
Enquire about a consultation